CYCLO THERAPEUTICS, INC. Clinical Trials
Studies registered on ClinicalTrials.gov (U.S. National Library of Medicine) with the company as lead sponsor or collaborator, newest start first. Values are as registered.
- 2022-09-23: Study NCT05607615; Company role Lead sponsor; Phase Phase 2; Status Unknown.
- 2021-07-20: Study NCT04860960; Company role Lead sponsor; Phase Phase 3; Status Unknown.
- 2019-05-23: Study NCT03893071; Company role Lead sponsor; Phase Phase 1; Status Unknown.
- 2017-10-11: Study NCT02939547; Company role Lead sponsor; Phase Phase 1; Status Completed.
| Start date | Study | Company role | Phase | Status | Conditions | Enrollment | Completion date |
|---|---|---|---|---|---|---|---|
| 2022-09-23 | NCT05607615 A 6-Month Study to Evaluate the Safety & Potential Efficacy of Trappsol Cyclo in Patients With Early Alzheimer's Disease | Lead sponsor | Phase 2 | Unknown | Alzheimer's Disease | 90 | 2024-03-31 |
| 2021-07-20 | NCT04860960 Phase 3 Study to Evaluate Intravenous Trappsol(R) Cyclo(TM) in Pediatric and Adult Patients With Niemann-Pick Disease Type C1 | Lead sponsor | Phase 3 | Unknown | Niemann-Pick Disease, Type C1 | 94 | 2026-06 |
| 2019-05-23 | NCT03893071 Open-Label Study of Long-Term Safety and Efficacy of Intravenous Trappsol Cyclo (HPβCD) in Niemann-Pick Disease Type C | Lead sponsor | Phase 1 | Unknown | Niemann-Pick Disease, Type C1 | 12 | 2022-03 |
| 2017-10-11 | NCT02939547 Study of the Pharmacokinetics of Trappsol and Effects on Potential Biomarkers of Niemann-Pick C1 (NPC1) | Lead sponsor | Phase 1 | Completed | Niemann-Pick Disease, Type C1 | 13 | 2020-02-10 |
| 2017-03-20 | NCT02912793 Safety and Efficacy of Intravenous Trappsol Cyclo (HPBCD) in Niemann-Pick Type C Patients | Lead sponsor | Phase 1, Phase 2 | Completed | Niemann-Pick Disease, Type C1 | 12 | 2021-03-03 |
| NCT03624842 Expanded Access With Trappsol(R) Cyclo (TM) for an Individual Patient With Late Onset Alzheimer's Disease | Lead sponsor | Expanded_access | No longer available | Late Onset Alzheimer Disease |